The Daily Bulletin Archive

Please join us for the Professional Science Master's seminar "A Medicinal Chemistry Story: Exploring the Glutamate Hypothesis using Glycine Transporter-1 (GlyT1) Inhibitors as Potential Therapy to Treat Schizophrenia," presented by Mark Wolf, Ph.D., section head of Medicinal Chemistry at Albany Molecular Research Inc. (AMRI) Buffalo, on Thursday, March 22, from 12:15 to 1:30 p.m. in Technology Building 160.

This presentation will focus on a medicinal chemistry project from early hit-to-lead through lead optimization. The design, synthesis, and structure–activity relationships (SAR) of a series of inhibitors of glycine transporter-1 (GlyT-1) will be described. The challenges faced by the program and the optimization of the core scaffold that led to the identification of a GlyT-1 inhibitor, which demonstrated in vivo activity in a rodent cerebral spinal fluid (CSF) glycine model, will be discussed.